Odontogenic ghost cell tumor

Dentinogenic ghost cell tumor (DGCT) is a rare, benign but locally aggressive odontogenic neoplasm characterized by ameloblastoma-like epithelial proliferation, ghost cells, and dentinoid material.[1][2] It is classified by the WHO as a mixed epithelial and mesenchymal odontogenic tumor and represents the solid neoplastic counterpart of the calcifying odontogenic cyst (COC).[3][4] DGCT occurs centrally (intraosseous) or, less commonly, as a peripheral (extraosseous) soft-tissue mass.[5][6] The pathogenesis involves aberrant activation of the WNT/β-catenin signaling pathway, with nuclear β-catenin accumulation detected in virtually all cases; underlying genetic alterations include loss-of-function mutations in WNT pathway tumor suppressor genes such as APC, SMURF1, and NEDD4L, while CTNNB1 hotspot mutations are infrequent.[7][8] Imaging typically reveals a mixed radiolucent-radiopaque lesion with well-defined borders and cortical expansion. Management requires surgical excision with adequate margins due to a significant recurrence tendency.[1][9]

The WHO 2017 (4th edition) classification designated this entity dentinogenic ghost cell tumor within the category of mixed epithelial and mesenchymal odontogenic tumors.[3] The 2022 WHO (5th edition) classification retains this designation with essential diagnostic criteria of solid tumor architecture, ameloblastoma-like epithelium, ghost cells, and dentinoid.[10]

• Accepted synonyms: odontogenic ghost cell tumor[5][11]
• Obsolete or historical terms: epithelial odontogenic ghost cell tumor; aggressive epithelial odontogenic ghost cell tumor; dentinogenic ghost cell ameloblastoma; solid variant of calcifying odontogenic cyst[12][13]

The relationship between DGCT and adenoid ameloblastoma (AA) is under active debate. Multiple molecular and histologic studies suggest AA and DGCT may represent a histologic spectrum of WNT pathway–altered benign odontogenic tumors rather than distinct entities, though the current WHO classification maintains them as separate types.[7][10][14]

• Frequency: DGCT is very rare, representing approximately 2% of all odontogenic tumors. COCs themselves account for only 1–2% of odontogenic tumors, with only about 2% of those presenting as solid tumors.[12][15]
• Age: Mean age at diagnosis is approximately 40 years (range 12–79 years). Pediatric cases are exceptionally rare.[1][16][17]
• Sex: Male predominance with a male-to-female ratio of approximately 1.8:1.[1]
• Location: The mandible and maxilla are affected in roughly equal proportions (mandible-to-maxilla ratio ~1.14:1), with the posterior regions of both jaws most commonly involved. The peripheral variant preferentially affects the anterior jaws.[1][6]

Central (intraosseous) DGCT

• Presentation: Painless or mildly painful jaw swelling is the most common complaint, often developing over months to years. Facial asymmetry may be the presenting sign, particularly in larger lesions.[1][16][18]
• Examination findings: Firm, non-tender bony expansion; dental mobility and displacement of adjacent teeth may be present. Maxillary lesions may extend into the maxillary sinus.[4][17][18]
• Tempo: Slow, progressive growth, though some cases demonstrate locally aggressive behavior with marked bone destruction and extraosseous extension.[19][20]
• Complications: Root resorption of adjacent teeth, cortical perforation, and rare malignant transformation to ghost cell odontogenic carcinoma (GCOC).[16][21]

Peripheral (extraosseous) DGCT

• Presents as a sessile or pedunculated gingival mass, typically in the anterior jaws. Mean size is smaller (~1.3 cm) than central lesions. Approximately 20% show erosion of the underlying bone. Peripheral lesions behave less aggressively than central counterparts.[5][6][22]

Location and distribution

Central DGCT arises within the body of the mandible or maxilla, with a predilection for the posterior regions of both jaws.[1] Occasional cases span the premolar-to-molar region or cross the midline in large tumors.[19] Maxillary lesions may occupy or extend into the maxillary sinus.[17][18]

Periphery and shape

• Most lesions (approximately 68%) demonstrate well-defined borders, often with a corticated or sclerotic rim.[1]
• Ill-defined margins are less common but may be seen in aggressive or recurrent cases.[20]
• The shape is typically round to ovoid; larger lesions may become lobulated.

Locularity

• Unilocular presentation predominates, reported in approximately 78% of cases.[1]
• Multilocular architecture occurs in a minority, sometimes with coarse internal septa. Multilocularity, when present, may suggest more aggressive behavior.[4][16]

Internal architecture

• The hallmark radiographic appearance is a mixed radiolucent and radiopaque internal pattern, observed in approximately 67% of cases. The radiopaque foci correspond histologically to calcified ghost cells, dystrophic calcification, and dentinoid material.[1][20]
• A minority of lesions appear purely radiolucent, particularly when calcification is minimal.[1][23]
• Scattered, irregular, or clustered radiopaque foci of variable size and density are characteristic; these may range from fine flecks to coarse masses.[18][19]
• On volumetric imaging, hypodense soft-tissue attenuation predominates with interspersed hyperdense foci. The heterogeneous density pattern correlates with the varying proportions of epithelial islands, ghost cell aggregates, dentinoid, and cystic areas.[17][18][20]

Effects on teeth and adjacent structures

• Root resorption of adjacent teeth is common and, when present, is a feature that helps distinguish DGCT from the less aggressive COC.[4][16]
• Tooth displacement and impaction of developing teeth may occur.[2][16]
• Association with an odontoma has been reported rarely.[2]

Cortical involvement and growth pattern

• Cortical expansion is typical, often with thinning of the buccal and/or lingual cortical plates.[16][17][19]
• Cortical perforation may occur in aggressive cases, with soft-tissue extension.[19][20]
• The peripheral variant produces saucerization or cupping of the underlying alveolar bone surface.[6][24]

Size

• Mean lesion size is approximately 4.0 cm (range 1.8–13.0 cm). Exceptionally large tumors with extraoral protrusion have been documented.[1][19]

Recognized variants on imaging

• Predominantly radiolucent lesions without appreciable calcification may mimic ameloblastoma or odontogenic keratocyst.
• Heavily calcified lesions may simulate odontoma or calcifying epithelial odontogenic tumor.
• Peripheral DGCT appears as a soft-tissue gingival mass, sometimes with underlying bone erosion visible on periapical or cross-sectional imaging.[6][24]

CT and MRI

When cross-sectional medical imaging is obtained for large or aggressive central DGCT, CT demonstrates a heterogeneous mass with soft-tissue attenuation and scattered calcifications causing marked mandibular or maxillary destruction.[20] On MRI, the tumor displays heterogeneous signal intensities on both T1- and T2-weighted sequences; areas of high cellularity, ghost cell aggregates, calcification, and cystic change each contribute distinct signal characteristics that correlate with histologic composition.[20] MRI is particularly useful for delineating soft-tissue extension into the floor of mouth, tongue base, or infratemporal fossa in aggressive cases.[20] These modalities are indicated when CBCT suggests cortical perforation, extensive soft-tissue involvement, or features raising concern for malignant transformation.

The mixed radiolucent-radiopaque internal pattern with cortical expansion in the posterior jaws generates a differential that includes other calcification-bearing odontogenic lesions and aggressive odontogenic tumors.

The highest-risk diagnostic pitfall is failure to distinguish DGCT from its malignant counterpart, GCOC. Incisional biopsy with thorough sampling is essential, as focal cytologic atypia in DGCT can mimic carcinoma; the definitive specimen may be required to exclude malignancy.[18]

Essential diagnostic features

The WHO 2022 essential criteria for DGCT require all four of the following:[10]

• Solid tumor architecture — predominantly solid proliferation rather than cystic
• Ameloblastoma-like odontogenic epithelium — islands, cords, and sheets of basaloid epithelium with peripheral palisading and reverse nuclear polarity resembling the enamel organ[2][5]
• Ghost cells — eosinophilic, swollen epithelial cells with faint nuclear outlines that have lost their nuclei; these may undergo dystrophic calcification and provoke a foreign-body giant cell reaction when they extend into the stroma[4][12]
• Dentinoid (dysplastic dentin) — eosinophilic, acellular or tubular matrix deposited at the epithelium-stroma interface, considered analogous to early dentinogenesis. Recent immunohistochemical evidence suggests this material may more closely resemble enameloid than true dentin, based on collagen type 1 positivity and amelogenin negativity.[4][31]

Architectural variants

The epithelial component may show pseudoglandular (cribriform) structures, fusiform areas, and whorls/morules.[18][19] These features overlap substantially with adenoid ameloblastoma, and the relative proportions of adenomatoid versus ghost cell/dentinoid components may vary dynamically, even within sequential specimens from the same patient.[21]

Immunohistochemistry

• β-catenin: Nuclear accumulation is consistently present and is the most reliable immunohistochemical marker, distinguishing DGCT from conventional ameloblastoma (which shows cytoplasmic β-catenin).[7][14]
• Cytokeratins: Positive for pan-CK, CK-14, CK-7, and CK-19.[19]
• Ki-67: Proliferative index is typically very low.[18][19][21]

Molecular findings affecting classification

WNT/β-catenin pathway activation is the unifying molecular feature shared by DGCT, COC, and adenoid ameloblastoma.[7][8] Loss-of-function mutations in APC, SMURF1, and NEDD4L have been identified, while CTNNB1 hotspot mutations are found in a minority of cases.[7] KRT13 (keratin 13) mutations have been detected in cases with abundant ghost cells, suggesting a role in ghost cell formation.[7] BRAF V600E mutation is rare in DGCT (~7%), in contrast to conventional ameloblastoma (~94%), providing a useful molecular discriminator.[14]

Radiologic-pathologic correlation

The mixed radiolucent-radiopaque imaging pattern directly reflects the heterogeneous histologic composition: radiolucent areas correspond to cellular epithelial islands and stromal tissue, while radiopaque foci correspond to calcified ghost cells, dystrophic mineralization, and dentinoid deposits.[20]

Surgical treatment

• Central DGCT: Resection with adequate bony margins (at least 0.5–1.0 cm, analogous to ameloblastoma protocols) is the recommended treatment. Conservative surgery (enucleation or curettage) carries a high recurrence rate of approximately 73% in cases with >1 year follow-up, whereas resection (marginal or segmental) reduces recurrence to approximately 33%.[1][9]
• Peripheral DGCT: Local excision with or without curettage of the underlying bone is sufficient; recurrence is rare.[5][6]

Recurrence and follow-up

• The high recurrence rate after conservative surgery underscores the locally aggressive nature of central DGCT. Five of seven patients treated conservatively in one series experienced recurrence and required subsequent resection.[1][9]
• Long-term clinical and radiographic surveillance is mandatory, as recurrences may develop years after initial treatment.[1][11]
• Recommended follow-up intervals have not been standardized, but periodic imaging at 6–12 month intervals for at least 5 years is prudent, with continued surveillance thereafter.

Malignant transformation

Rare transformation to GCOC has been documented, either de novo or following recurrence of DGCT or COC.[21][29] Increasing Ki-67 proliferative index and architectural plasticity during recurrence may herald malignant progression.[21] This possibility reinforces the need for histopathologic evaluation of all recurrent lesions.

Prognosis

Overall prognosis is favorable when adequately resected. Peripheral lesions carry an excellent prognosis with near-zero recurrence after excision.[6] For central lesions, prognosis depends primarily on the adequacy of surgical margins and the completeness of initial resection.[1][9]

Relationship to the ghost cell odontogenic lesion spectrum

DGCT exists within a biologic continuum of ghost cell–containing odontogenic lesions that includes COC (cystic, indolent), DGCT (solid, locally aggressive), and GCOC (malignant).[21][24] Longitudinal intra-patient studies have demonstrated progression from COC to DGCT to GCOC, with stable molecular profiles but shifting architectural phenotypes across stages.[21] This spectrum has implications for surveillance: even lesions initially diagnosed as COC warrant follow-up, as solid recurrence may represent DGCT, and subsequent transformation to GCOC is possible.

Adenoid ameloblastoma overlap

The substantial clinical, histologic, and molecular overlap between DGCT and adenoid ameloblastoma has prompted proposals to unify these entities.[7][10][14] Pathologists should be aware that prior to the 2022 WHO classification, some adenoid ameloblastomas may have been classified as DGCT, potentially affecting published epidemiologic and outcome data.[10]